Hugo Kubinyi

from Wikipedia, the free encyclopedia

Hugo Kubinyi (* 1940 in Vienna ) is an Austrian chemist ( pharmaceutical chemistry , drug design ).

Kubinyi studied chemistry in Vienna from 1958 and received his doctorate in 1965 at the Ludwig Maximilians University in Munich under Adolf Butenandt and Erich Hecker (isolation, structure and partial synthesis of biologically active natural substances from croton oil), with the dissertation at the Max Planck Institute for Biochemistry in Munich was made. As a post-doctoral student he was at the German Cancer Research Center in Heidelberg in 1965/66 . From 1966 he was at Knoll AG (which later came to BASF, now Abbott), where he dealt with natural product chemistry and developed partially synthetic cardiac glycosides (meproscillarin, approved from 1978). From 1972 he headed the research department there. In 1978 he completed his habilitation at the University of Heidelberg (lipophilicity and biological activity: a contribution to quantitative structure-activity relationships), where he was professor of pharmaceutical chemistry from 1986. From 1985 he was with BASF , from which he retired in 2001. From 1987 he was responsible for the active ingredient design, molecular modeling and X-ray crystallography of proteins and from 1998 also for combinatorial chemistry in the biosciences. In particular, he researched QSAR methods and structure-activity relationships.

Together with Hans-Joachim Böhm and Gerhard Klebe, he received the Literature Prize of the Fonds der Chemischen Industrie for their book on drug design.

From 1995 to 2001 he chaired the Cheminformatics and QSAR Society. In 2006 he received the Herman Skolnik Award and in 2008 the Nauta Award in Pharmacochemistry from the European Federation for Medicinal Chemistry (EFMC) and was also a Nauta visiting professor at the Free University of Amsterdam. He is an IUPAC Fellow.

He is co-editor of the Methods and Principles in Medicinal Chemistry book series at Wiley-VCH.

Fonts

  • with Hans-Joachim Böhm, Gerhard Klebe: Active substance design, spectrum Akademischer Verlag 1996
  • with G. Müller (Ed.): Chemogenomics in Drug Discovery - A Medicinal Chemistry Perspective, Methods and Principles in Medicinal Chemistry, Volume 22, Wiley-VCH 2004
  • QSAR. Hansch Analysis and Related Approaches, in R. Mannhold, P. Kroogsgard-Larsen, H. Timmermann (Eds.): Methods and Principles in Medicinal Chemistry, Volume 1, VCH, Weinheim 1993
  • Editor: 3D QSAR in Drug Design. Theory, Methods and Applications, ESCOM, Science Publishers BV, Leiden, 1993.
  • Editor with G. Folkers, YC Martin: 3D QSAR in Drug Design, Volume 2 :. Ligand-Protein Complexes and Molecular Similarity, Kluwer / ESCOM, Dordrecht, 1998 (also in Persp. Drug Discov. Design 9-11, 1998)
  • Editor with G. Folkers, YC Martin: 3D QSAR in Drug Design, Volume 3: Recent Advances, Kluwer / ESCOM, Dordrecht, 1998 (also in Persp. Drug Discov. Design 12-14, 1998)
  • Editor: Drug Discovery Technologies, Comprehensive Medicinal Chemistry II (Ed. JB Taylor, DJ Triggle), Volume 3, Elsevier, Oxford, 2007 (therein by Kubinyi: Chemogenomics in Drug Discovery, pp. 921-937)
  • The Drug Discovery Process, in: Wiley Handbook of Current and Emerging Drug Therapies, John Wiley & Sons, Hoboken, NJ, 2006, pp. 3-23.
  • The Changing Landscape in Drug Discovery, in: RM Stroud (Ed.), Computational Approaches to Structure Based Drug Design, Royal Society of Chemistry, London, 2007, pp. 24–45.
  • Lead structures - the start of the drug, Österreichische Apotheker-Zeitung, Volume 60, 2006, pp. 1112–1115

Web links

personal data
SURNAME Kubinyi, Hugo
BRIEF DESCRIPTION Austrian chemist
DATE OF BIRTH 1940
PLACE OF BIRTH Vienna